Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons

Nonsense mutations that generate a premature termination codon (PTC) can induce both the accelerated degradation of mutated mRNA compared with the wild type version of the mRNA or the production of a truncated protein. One of the considered therapeutic strategies to bypass PTCs is their “readthrough” based on small-molecule drugs. These molecules promote the incorporation of a near-cognate tRNA at the PTC position through the native polypeptide chain. In this review, we detailed the various existing strategies organized according to pharmacological molecule types through their different mechanisms. The positive results that followed readthrough molecule testing in multiple neuromuscular disorder models indicate the potential of this approach in peripheral neuropathies.

[1]  O. Namy,et al.  TLN468 changes the pattern of tRNA used to read through premature termination codons in CFTR , 2024, bioRxiv.

[2]  L. Richard,et al.  Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene , 2023, Pharmaceuticals.

[3]  A. Di Leonardo,et al.  Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2′-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTR , 2023, International journal of molecular sciences.

[4]  P. Reix,et al.  Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  M. Tutone,et al.  Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Joshua L Schwartz,et al.  AKT constitutes a signal-promoted alternative exon-junction complex that regulates nonsense-mediated mRNA decay. , 2022, Molecular cell.

[7]  B. Cooperman,et al.  Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination , 2022, Nature Communications.

[8]  M. del Río,et al.  Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants. , 2022, JAMA dermatology.

[9]  F. Sturtz,et al.  From Negative to Positive Diagnosis: Structural Variation Could Be the Second Mutation You Are Looking for in a Recessive Autosomal Gene , 2022, Journal of personalized medicine.

[10]  O. Namy,et al.  2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases , 2021, bioRxiv.

[11]  H. Le Hir,et al.  A role for AKT1 in nonsense-mediated mRNA decay , 2021, Nucleic acids research.

[12]  G. Koppelman,et al.  Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  L. Richard,et al.  GDAP1 Involvement in Mitochondrial Function and Oxidative Stress, Investigated in a Charcot-Marie-Tooth Model of hiPSCs-Derived Motor Neurons , 2021, Biomedicines.

[14]  R. Green,et al.  A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion , 2021, Nature Communications.

[15]  C. Dieterich,et al.  SMG5-SMG7 authorize nonsense-mediated mRNA decay by enabling SMG6 endonucleolytic activity , 2021, Nature Communications.

[16]  R. Chai,et al.  Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides , 2021, Frontiers in Cellular Neuroscience.

[17]  S. Flibotte,et al.  Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough , 2021, PLoS biology.

[18]  S. Tenzer,et al.  GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton , 2021, Communications Biology.

[19]  M. Goddeeris,et al.  Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  B. Cooperman,et al.  Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms , 2021, Proceedings of the National Academy of Sciences.

[21]  M. Pinotti,et al.  Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches , 2020, International journal of molecular sciences.

[22]  C. Raoul,et al.  Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay , 2020, Scientific Reports.

[23]  T. Spicer,et al.  Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR , 2020, SLAS discovery : advancing life sciences R & D.

[24]  E. Kerem.  ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease , 2020, Expert opinion on investigational drugs.

[25]  A. Di Leonardo,et al.  Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems , 2020, International journal of molecular sciences.

[26]  G. Piluso,et al.  The position of nonsense mutations can predict the phenotype severity: A survey on the DMD gene , 2020, PloS one.

[27]  Yi-Tao Yu,et al.  Suppression of Nonsense Mutations by New Emerging Technologies , 2020, International journal of molecular sciences.

[28]  M. Goddeeris,et al.  ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[29]  J. Rientjes,et al.  Effect of Ataluren on dystrophin mutations , 2020, Journal of cellular and molecular medicine.

[30]  E. Westhof,et al.  2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations , 2020, Nature Communications.

[31]  J. Alfaro,et al.  Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics , 2020, Cancers.

[32]  K. Nagel-Wolfrum,et al.  Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations , 2019, International journal of molecular sciences.

[33]  E. Haseltine,et al.  A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[34]  Shuling Guo,et al.  Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations , 2019, Nucleic acid therapeutics.

[35]  Etienne Raimondeau,et al.  New insights into the interplay between the translation machinery and nonsense-mediated mRNA decay factors , 2018, Biochemical Society transactions.

[36]  O. Namy,et al.  Deciphering the reading of the genetic code by near-cognate tRNA , 2018, Proceedings of the National Academy of Sciences.

[37]  R. B. Altman,et al.  Aminoglycoside interactions and impacts on the eukaryotic ribosome , 2017, Proceedings of the National Academy of Sciences.

[38]  P. Reix,et al.  Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases , 2017, PloS one.

[39]  H. Shimizu,et al.  Gentamicin-Induced Readthrough and Nonsense-Mediated mRNA Decay of SERPINB7 Nonsense Mutant Transcripts. , 2017, The Journal of investigative dermatology.

[40]  R. Finkel,et al.  Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[41]  D. Gruenert,et al.  Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins , 2017, Journal of Cell Science.

[42]  J. Uitto,et al.  Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa. , 2017, The Journal of investigative dermatology.

[43]  D. Keene,et al.  Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients , 2017, The Journal of clinical investigation.

[44]  O. Namy,et al.  Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells , 2017, RNA biology.

[45]  P. Sergiev,et al.  2-Guanidino-quinazolines as a novel class of translation inhibitors. , 2017, Biochimie.

[46]  M. Erlacher,et al.  Atomic mutagenesis at the ribosomal decoding site , 2016, RNA Biology.

[47]  A. Jacobson,et al.  Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression , 2016, Proceedings of the National Academy of Sciences.

[48]  L. da Cruz,et al.  Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model. , 2016, Human molecular genetics.

[49]  S. Thoms,et al.  Functional Translational Readthrough: A Systems Biology Perspective , 2016, PLoS genetics.

[50]  B. Eliseev,et al.  PABP enhances release factor recruitment and stop codon recognition during translation termination , 2016, Nucleic acids research.

[51]  S. Flibotte,et al.  Novel small molecules potentiate premature termination codon readthrough by aminoglycosides , 2016, Nucleic acids research.

[52]  K. Krause,et al.  Aminoglycosides: An Overview. , 2016, Cold Spring Harbor perspectives in medicine.

[53]  Weibo Cai,et al.  NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. , 2016, Bioconjugate chemistry.

[54]  Narayana Murthy Sabbavarapu,et al.  Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations. , 2016, ACS medicinal chemistry letters.

[55]  Bruce L Miller,et al.  Frontotemporal dementia , 2015, The Lancet.

[56]  E. Ziętkiewicz,et al.  Translational readthrough potential of natural termination codons in eucaryotes – The impact of RNA sequence , 2015, RNA biology.

[57]  L. Takada.  The Genetics of Monogenic Frontotemporal Dementia , 2015, Dementia & neuropsychologia.

[58]  Paula Juárez,et al.  Lack of GDAP1 Induces Neuronal Calcium and Mitochondrial Defects in a Knockout Mouse Model of Charcot-Marie-Tooth Neuropathy , 2015, PLoS genetics.

[59]  J. Cáceres,et al.  The RNA Helicase DHX34 Activates NMD by Promoting a Transition from the Surveillance to the Decay-Inducing Complex , 2014, Cell reports.

[60]  Kurt A. Wargo,et al.  Aminoglycoside-Induced Nephrotoxicity , 2014, Journal of pharmacy practice.

[61]  Nicola J. Ryan.  Ataluren: First Global Approval , 2014, Drugs.

[62]  J. Lupski,et al.  The allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals with neuropathy , 2014, Molecular genetics & genomic medicine.

[63]  S. Peltz,et al.  Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Respiratory medicine.

[64]  Alka A. Potdar,et al.  Programmed Translational Readthrough Generates Antiangiogenic VEGF-Ax , 2014, Cell.

[65]  J. Schacht,et al.  Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. , 2014, American journal of respiratory cell and molecular biology.

[66]  L. Valášek,et al.  Translation Initiation Factors eIF3 and HCR1 Control Translation Termination and Stop Codon Read-Through in Yeast Cells , 2013, PLoS genetics.

[67]  R. Damoiseaux,et al.  A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  O. Mühlemann,et al.  Nonsense-mediated mRNA decay - mechanisms of substrate mRNA recognition and degradation in mammalian cells. , 2013, Biochimica et biophysica acta.

[69]  S. Peltz,et al.  Ataluren as an agent for therapeutic nonsense suppression. , 2013, Annual review of medicine.

[70]  V. Belakhov,et al.  Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations. , 2012, Journal of medicinal chemistry.

[71]  J. Dougherty,et al.  Pharmaceutical therapies to recode nonsense mutations in inherited diseases. , 2012, Pharmacology & therapeutics.

[72]  U. Wolfrum,et al.  A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation , 2012, EMBO molecular medicine.

[73]  M. Jung,et al.  Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. , 2012, Human molecular genetics.

[74]  K. Mamchaoui,et al.  Rescue of nonsense mutations by amlexanox in human cells , 2012, Orphanet Journal of Rare Diseases.

[75]  H. Urlaub,et al.  The cryo-EM structure of the UPF–EJC complex shows UPF1 poised toward the RNA 3′ end , 2012, Nature Structural &Molecular Biology.

[76]  J. Rousset,et al.  Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to Gentamicin , 2012, PLoS genetics.

[77]  S. Napthine,et al.  Characterization of the stop codon readthrough signal of Colorado tick fever virus segment 9 RNA. , 2012, RNA.

[78]  Silvia Domcke,et al.  Molecular mechanisms for the RNA-dependent ATPase activity of Upf1 and its regulation by Upf2. , 2011, Molecular cell.

[79]  J. Rousset,et al.  Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides , 2010, Nucleic acids research.

[80]  U. Wolfrum,et al.  Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina. , 2010, Investigative ophthalmology & visual science.

[81]  E. Eyal,et al.  The Effect of Gentamicin-Induced Readthrough on a Novel Premature Termination Codon of CD18 Leukocyte Adhesion Deficiency Patients , 2010, PloS one.

[82]  J. Mendell,et al.  Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophy , 2010, Annals of neurology.

[83]  V. Belakhov,et al.  Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. , 2010, Bioorganic & medicinal chemistry.

[84]  K. Bushby,et al.  Molecular treatments in Duchenne muscular dystrophy. , 2010, Current opinion in pharmacology.

[85]  C. Lorson,et al.  Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. , 2009, Human molecular genetics.

[86]  R. Damoiseaux,et al.  Nonaminoglycoside compounds induce readthrough of nonsense mutations , 2009, The Journal of experimental medicine.

[87]  J. Schacht,et al.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. , 2009, Journal of medicinal chemistry.

[88]  Y. Ham,et al.  Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics , 2009, Perspectives in medicinal chemistry.

[89]  D. Auld,et al.  Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression , 2009, Proceedings of the National Academy of Sciences.

[90]  Guojun Wang,et al.  A Novel Insertion Mutation in Streptomyces coelicolor Ribosomal S12 Protein Results in Paromomycin Resistance and Antibiotic Overproduction , 2008, Antimicrobial Agents and Chemotherapy.

[91]  O. Mühlemann,et al.  Recognition and elimination of nonsense mRNA. , 2008, Biochimica et biophysica acta.

[92]  Matthew Mort,et al.  A meta‐analysis of nonsense mutations causing human genetic disease , 2008, Human mutation.

[93]  O. Guthrie,et al.  Aminoglycoside induced ototoxicity. , 2008, Toxicology.

[94]  J. Lykke-Andersen,et al.  A Competition between Stimulators and Antagonists of Upf Complex Recruitment Governs Human Nonsense-Mediated mRNA Decay , 2008, PLoS biology.

[95]  M. Hentze,et al.  Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways , 2008, The EMBO journal.

[96]  S. Peltz,et al.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.

[97]  A. J. Schroeder,et al.  Revisiting the protein-coding gene catalog of Drosophila melanogaster using 12 fly genomes. , 2007, Genome research.

[98]  Hua Fan-Minogue,et al.  Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. , 2007, RNA.

[99]  J. Tazi,et al.  Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies , 2007, The Journal of cell biology.

[100]  J. Holton,et al.  Structural basis for aminoglycoside inhibition of bacterial ribosome recycling , 2007, Nature Structural &Molecular Biology.

[101]  M. Hentze,et al.  The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway , 2007, Nucleic acids research.

[102]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[103]  T. Hermann,et al.  Aminoglycoside antibiotics: old drugs and new therapeutic approaches , 2007, Cellular and Molecular Life Sciences.

[104]  T. Baasov,et al.  Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. , 2006, Bioorganic & medicinal chemistry letters.

[105]  S. Melquist,et al.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.

[106]  L. Maquat,et al.  Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. , 2006, Trends in molecular medicine.

[107]  E. Hol,et al.  hUPF2 Silencing Identifies Physiologic Substrates of Mammalian Nonsense-Mediated mRNA Decay , 2006, Molecular and Cellular Biology.

[108]  G. Dreyfuss,et al.  Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. , 2006, Genes & development.

[109]  R. Gatti,et al.  Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Francisco Martinez-Murillo,et al.  Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise , 2004, Nature Genetics.

[111]  T. Ohnishi,et al.  Inhibition of nonsense‐mediated mRNA decay rescues the phenotype in Ullrich's disease , 2004, Annals of neurology.

[112]  J. Rousset,et al.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment , 2004, Gene Therapy.

[113]  J. Lupski,et al.  Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations , 2004, Nature Genetics.

[114]  Isabelle Hatin,et al.  The major 5' determinant in stop codon read-through involves two adjacent adenines. , 2004, Nucleic acids research.

[115]  B. Kerem,et al.  Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. , 2003, The New England journal of medicine.

[116]  Eric Westhof,et al.  RNA as a Drug Target: The Case of Aminoglycosides , 2003, Chembiochem : a European journal of chemical biology.

[117]  L. Maquat,et al.  Nonsense-mediated mRNA decay in mammalian cells involves decapping, deadenylating, and exonucleolytic activities. , 2003, Molecular cell.

[118]  Steven E. Brenner,et al.  Widespread predicted nonsense-mediated mRNA decay of alternatively-spliced transcripts of human normal and disease genes , 2003, ISMB.

[119]  Hanns Lochmüller,et al.  Gentamicin fails to increase dystrophin expression in dystrophin‐deficient muscle , 2003, Muscle & nerve.

[120]  M. Lynch,et al.  Messenger RNA surveillance and the evolutionary proliferation of introns. , 2003, Molecular biology and evolution.

[121]  S. Brenner,et al.  Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[122]  M. Evans,et al.  Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene , 2002, Journal of Molecular Medicine.

[123]  Y. Bignon,et al.  Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. , 2002, International journal of oncology.

[124]  V. Ramakrishnan,et al.  Ribosome Structure and the Mechanism of Translation , 2002, Cell.

[125]  Y. Taya,et al.  Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. , 2001, Genes & development.

[126]  E Westhof,et al.  Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. , 2001, Structure.

[127]  K. Fischbeck,et al.  Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations , 2001, Annals of neurology.

[128]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[129]  Jean-Pierre Rousset,et al.  UAG readthrough in mammalian cells: Effect of upstream and downstream stop codon contexts reveal different signals , 2001, BMC Molecular Biology.

[130]  H. Le Hir,et al.  The spliceosome deposits multiple proteins 20–24 nucleotides upstream of mRNA exon–exon junctions , 2000, The EMBO journal.

[131]  V. Ramakrishnan,et al.  Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics , 2000, Nature.

[132]  S. Peltz,et al.  Characterization of the biochemical properties of the human Upf1 gene product that is involved in nonsense-mediated mRNA decay. , 2000, RNA.

[133]  A. Avital,et al.  A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. , 2000, American journal of respiratory and critical care medicine.

[134]  H. Sweeney,et al.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. , 1999, The Journal of clinical investigation.

[135]  J. Schacht,et al.  Stimulation of free radical formation by aminoglycoside antibiotics 1 The data in this paper have been presented, in part, at the meeting of the Association for Research in Otolaryngology, February 1996. 1 , 1999, Hearing Research.

[136]  J. Puglisi,et al.  Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. , 1998, Journal of molecular biology.

[137]  Chris M. Brown,et al.  The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. , 1995, The EMBO journal.

[138]  R. Martin,et al.  Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. , 1994, Nucleic acids research.

[139]  C. Rice,et al.  The signal for translational readthrough of a UGA codon in Sindbis virus RNA involves a single cytidine residue immediately downstream of the termination codon , 1993, Journal of virology.

[140]  J. Clegg,et al.  Molecular basis for dominantly inherited inclusion body beta-thalassemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[141]  J. Burke,et al.  Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. , 1985, Nucleic acids research.

[142]  M. Barciszewska,et al.  UAG readthrough during TMV RNA translation: isolation and sequence of two tRNAsTyr with suppressor activity from tobacco plants , 1984, The EMBO journal.

[143]  G. Laurent,et al.  Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. , 1982, Biochemical pharmacology.

[144]  H. Pelham.  Leaky UAG termination codon in tobacco mosaic virus RNA , 1978, Nature.

[145]  C. Weissmann,et al.  The readthrough protein A1 is essential for the formation of viable Qβ particles , 1974 .

[146]  S. Waksman,et al.  Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.∗† , 1944, Clinical orthopaedics and related research.

[147]  D. Pearce,et al.  The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy. , 2015, Human molecular genetics.

[148]  D. Bedwell,et al.  Therapies of Nonsense-Associated Diseases , 2013 .

[149]  G. Dale,et al.  Emerging New Therapeutics Against Key Gram-Negative Pathogens , 2011 .

[150]  J. Puglisi,et al.  Comparison of X-ray crystal structure of the 30S subunit-antibiotic complex with NMR structure of decoding site oligonucleotide-paromomycin complex. , 2003, Structure.

[151]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[152]  W. Tate,et al.  Hidden infidelities of the translational stop signal. , 1996, Progress in nucleic acid research and molecular biology.

[153]  L. Maquat,et al.  Cytoplasmic mRNA for human triosephosphate isomerase is immune to nonsense-mediated decay despite forming polysomes. , 1996, Biochimie.

[154]  Identi fi cation and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations , 2022 .